Allen B et al.,“Abundant tau filaments and nonapoptotic neurodegenera tion in transgenic
mice expressing human P301S tau protein”, The Journal of Neuroscience, Nov. 1, 2002 vol …

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such
as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degen …

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such
as Alzheimer's disease, Pick's disease, progressive Supranuclear palsy, corticobasal degen …

US20170173016A1 - Heterocyclic compounds and their use for the treatment of
neurodegenerative tauopathies - Google Patents US20170173016A1 - Heterocyclic …

The present invention relates to compounds of formulae I and H, or pharmaceutically
acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical …

Related US Application Data Disclosed are compounds of formula (1)–(V): where the
substituents are as provided herein. Further disclosed are (60) Provisional application No …

US11661580B2 - Method of inhibiting tau phosphorylation - Google Patents
US11661580B2 - Method of inhibiting tau phosphorylation - Google Patents Method of …

US20200121666A1 - Tau phosphorylation inhibitors and methods for treating or preventing
alzheimer's disease - Google Patents US20200121666A1 - Tau phosphorylation inhibitors and …

Disclosed are compounds of formula (1)-(V): where the substituents are as provided herein.
Further disclosed are methods of inhibiting tau aggregation, treating or amelio rating a …

(57) ABSTRACT A compound represented by the formula (I), an optically active isomer
thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N …